144 related articles for article (PubMed ID: 36944149)
1. Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.
Plichta JK; Thomas SM; Hayes DF; Chavez-MacGregor M; Allison K; de Los Santos J; Fowler AM; Giuliano AE; Sharma P; Smith BD; van Eycken E; Edge SB; Hortobagyi GN
J Clin Oncol; 2023 May; 41(14):2546-2560. PubMed ID: 36944149
[TBL] [Abstract][Full Text] [Related]
2. Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer.
Berg T; Jensen MB; Rossing M; Bechmann T; Donskov F; Knoop AS; Ejlertsen B
JAMA Netw Open; 2024 Mar; 7(3):e242174. PubMed ID: 38477916
[TBL] [Abstract][Full Text] [Related]
3. A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates.
Plichta JK; Thomas SM; Sergesketter AR; Greenup RA; Rosenberger LH; Fayanju OM; Kimmick G; Force J; Hyslop T; Hwang ES
Ann Surg; 2022 Apr; 275(4):784-792. PubMed ID: 32657941
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
5. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Kommalapati A; Tella SH; Goyal G; Ganti AK; Krishnamurthy J; Tandra PK
Breast Cancer Res Treat; 2018 Aug; 170(3):677-685. PubMed ID: 29721715
[TBL] [Abstract][Full Text] [Related]
6. An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma.
Chan SK; O'Sullivan B; Huang SH; Chau TC; Lam KO; Chan SY; Tong CC; Vardhanabhuti V; Kwong DL; Ng CY; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454830
[TBL] [Abstract][Full Text] [Related]
7. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.
Chavez-MacGregor M; Mittendorf EA; Clarke CA; Lichtensztajn DY; Hunt KK; Giordano SH
Oncologist; 2017 Nov; 22(11):1292-1300. PubMed ID: 28592619
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
9. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
Malmgren JA; Mayer M; Atwood MK; Kaplan HG
Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma.
Husain ZA; Chen T; Corso CD; Wang Z; Park H; Judson B; Yarbrough W; Deshpande H; Mehra S; Kuo P; Decker RH; Burtness BA
JAMA Oncol; 2017 Mar; 3(3):358-365. PubMed ID: 27737449
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer.
Xu L; Li JH; Ye JM; Duan XN; Cheng YJ; Xin L; Liu Q; Zhou B; Liu YH
Chin Med J (Engl); 2017 Aug; 130(16):1945-1952. PubMed ID: 28776547
[TBL] [Abstract][Full Text] [Related]
13. Metastatic breast cancer: Who benefits from surgery?
Marks CE; Thomas SM; Fayanju OM; DiLalla G; Sammons S; Hwang ES; Plichta JK
Am J Surg; 2022 Jan; 223(1):81-93. PubMed ID: 34325907
[TBL] [Abstract][Full Text] [Related]
14. [The 8th edition of the American Joint Committee on Cancer staging system provide improved prognostic accuracy in T1-2N1M0 postmastectomy breast cancer patients].
Sun GY; Wang SL; Tang Y; Yang Y; Fang H; Wang JY; Jing H; Zhang JH; Jin J; Song YW; Liu YP; Chen B; Qi SN; Li N; Tang Y; Lu NN; Wang WH; Chen SY; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2019 Aug; 41(8):615-623. PubMed ID: 31434454
[No Abstract] [Full Text] [Related]
15. De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
Gaillard T; Carton M; Mailliez A; Desmoulins I; Mouret-Reynier MA; Petit T; Leheurteur M; Dieras V; Ferrero JM; Uwer L; Guiu S; Gonçalves A; Levy C; Debled M; Dalenc F; Patsouris A; Bachelot T; Eymard JC; Chevrot M; Conversano A; Robain M; Hequet D
Eur J Cancer; 2021 Oct; 158():181-188. PubMed ID: 34689042
[TBL] [Abstract][Full Text] [Related]
16. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis.
Wu SG; Li H; Tang LY; Sun JY; Zhang WW; Li FY; Chen YX; He ZY
Tumour Biol; 2017 Jun; 39(6):1010428317705082. PubMed ID: 28653887
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.
Wang M; Chen H; Wu K; Ding A; Zhang M; Zhang P
Breast; 2018 Feb; 37():56-63. PubMed ID: 29100045
[TBL] [Abstract][Full Text] [Related]
18. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
Seltzer S; Corrigan M; O'Reilly S
Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942
[TBL] [Abstract][Full Text] [Related]
19. Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer.
Keane FK; Chen YH; Tishler RB; Schoenfeld JD; Haddad RI; Goguen LA; Catalano P; Neville BA; Margalit DN
Head Neck; 2016 Oct; 38(10):1530-8. PubMed ID: 27080700
[TBL] [Abstract][Full Text] [Related]
20. Genomic Characterization of
Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU
Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
